<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676231</url>
  </required_header>
  <id_info>
    <org_study_id>SGM-1019-102</org_study_id>
    <nct_id>NCT03676231</nct_id>
  </id_info>
  <brief_title>Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SGM-1019 Administered for 12 Weeks in Subjects With F1-F3 Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Genome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Genome</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the
      safety, pharmacokinetics, and pharmacodynamics of 12 weeks' administration of SGM-1019 in
      subjects with fibrosis stage 1-3 (F1-F3) NASH.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to a safety event which rendered the risk-benefit profile in NASH to no
    longer be adequately favorable
  </why_stopped>
  <start_date type="Actual">January 18, 2019</start_date>
  <completion_date type="Actual">May 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Safety and Tolerability - Treatment-emergent Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Summary of treatment emergent adverse events coded using MedDRA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetics - PK</measure>
    <time_frame>12 weeks</time_frame>
    <description>Peak plasma concentration of SGM-1019 as measured by Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacodynamics - Labs</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluation of liver functions labs of ALT, AST, ALP, and bilirubin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Phamacodynamics - MRI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluation of MRI parameters for assessment of liver fat, fibroinflammation, and stiffness.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>High-dose SGM-1019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose SGM-1019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGM-1019</intervention_name>
    <description>Active</description>
    <arm_group_label>High-dose SGM-1019</arm_group_label>
    <arm_group_label>Low-dose SGM-1019</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Age 18 to 75 years, inclusive

          -  Elevated ALT

          -  F1-F3 NASH

          -  BMI â‰¥ 25

        Exclusion Criteria:

          -  Use of prohibited medication/supplements

          -  Poorly controlled type 2 diabetes

          -  Hepatic decompensation

          -  Chronic liver disease

          -  Planned surgeries/procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew W McClure, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Second Genome</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Second Genome Clinical Site 405</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Genome Clinical Site 406</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Genome Clinical Site 403</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Genome Clinical Site 409</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Genome Clinical Site 410</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Genome Clinical Site 404</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Genome Clinical Site 408</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Genome Clinical Site 407</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Genome Clinical Site 402</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Genome Clinical Site 401</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

